x
|
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
||
For the quarterly period ended September 30, 2012
|
¨
|
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
||
For transition period from to
|
Delaware
|
94-3023969
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number)
|
Large accelerated filer x
|
Accelerated filer ¨
|
Non-accelerated filer ¨
|
Smaller reporting company ¨
|
(Do not check if a smaller reporting company)
|
Page
|
||
PART I - FINANCIAL INFORMATION
|
||
ITEM 1.
|
FINANCIAL STATEMENTS
|
|
Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2012 and 2011
|
3
|
|
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2012 and 2011
|
4
|
|
Condensed Consolidated Balance Sheets at September 30, 2012, and December 31, 2011
|
5
|
|
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011
|
6
|
|
Notes to the Condensed Consolidated Financial Statements
|
7
|
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
21
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
32
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
34
|
PART II - OTHER INFORMATION
|
||
ITEM 1.
|
LEGAL PROCEEDINGS
|
35
|
ITEM 1A.
|
RISK FACTORS
|
37
|
ITEM 6.
|
EXHIBITS
|
38
|
SIGNATURES
|
39
|
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Revenues
|
||||||||||||||||
Royalties
|
$ | 85,231 | $ | 83,370 | $ | 288,479 | $ | 278,833 | ||||||||
License and other
|
- | 400 | - | 10,400 | ||||||||||||
Total revenues
|
85,231 | 83,770 | 288,479 | 289,233 | ||||||||||||
Operating expenses
|
||||||||||||||||
General and administrative
|
5,647 | 3,960 | 17,737 | 13,516 | ||||||||||||
Operating income
|
79,584 | 79,810 | 270,742 | 275,717 | ||||||||||||
Non-operating expense, net
|
||||||||||||||||
Loss on retirement or conversion of convertible notes
|
- | - | - | (766 | ) | |||||||||||
Interest and other income, net
|
1,867 | 130 | 2,385 | 463 | ||||||||||||
Interest expense
|
(6,514 | ) | (9,007 | ) | (23,087 | ) | (27,941 | ) | ||||||||
Total non-operating expense, net
|
(4,647 | ) | (8,877 | ) | (20,702 | ) | (28,244 | ) | ||||||||
Income before income taxes
|
74,937 | 70,933 | 250,040 | 247,473 | ||||||||||||
Income tax expense
|
26,362 | 25,017 | 87,779 | 87,026 | ||||||||||||
Net income
|
$ | 48,575 | $ | 45,916 | $ | 162,261 | $ | 160,447 | ||||||||
Net income per share
|
||||||||||||||||
Basic
|
$ | 0.35 | $ | 0.33 | $ | 1.16 | $ | 1.15 | ||||||||
Diluted
|
$ | 0.32 | $ | 0.28 | $ | 1.08 | $ | 0.88 | ||||||||
Weighted average shares outstanding
|
||||||||||||||||
Basic
|
139,715 | 139,680 | 139,693 | 139,665 | ||||||||||||
Diluted
|
149,626 | 167,019 | 150,678 | 186,756 | ||||||||||||
Cash dividends declared per common share
|
$ | - | $ | - | $ | 0.60 | $ | 0.60 |
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Net income
|
$ | 48,575 | $ | 45,916 | $ | 162,261 | $ | 160,447 | ||||||||
Other comprehensive income (loss), net of tax
|
||||||||||||||||
Unrealized losses on investments in available-for-sale securities
|
(14 | ) | (55 | ) | (1 | ) | (8 | ) | ||||||||
Unrealized gains (losses) on cash flow hedges
|
(3,126 | ) | 4,281 | (853 | ) | (4,981 | ) | |||||||||
Total other comprehensive income (loss), net of tax
|
(3,140 | ) | 4,226 | (854 | ) | (4,989 | ) | |||||||||
Comprehensive income
|
$ | 45,435 | $ | 50,142 | $ | 161,407 | $ | 155,458 |
September 30,
2012 |
December 31,
2011 |
|||||||
(unaudited)
|
(Note 1)
|
|||||||
Assets | ||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 132,590 | $ | 168,544 | ||||
Restricted investment
|
20,000 | - | ||||||
Short-term investments
|
27,777 | 42,301 | ||||||
Receivables from licensees
|
- | 600 | ||||||
Deferred tax assets
|
3,552 | 10,054 | ||||||
Notes receivable
|
13,182 | - | ||||||
Prepaid and other current assets
|
5,775 | 12,014 | ||||||
Total current assets
|
202,876 | 233,513 | ||||||
Property and equipment, net
|
30 | 22 | ||||||
Long-term investments
|
- | 17,101 | ||||||
Notes receivable
|
33,490 | - | ||||||
Long-term deferred tax assets
|
6,162 | 11,481 | ||||||
Other assets
|
7,338 | 7,354 | ||||||
Total assets
|
$ | 249,896 | $ | 269,471 | ||||
Liabilities and Stockholders' Deficit
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$ | 813 | $ | 528 | ||||
Accrued legal settlement
|
- | 27,500 | ||||||
Accrued liabilities
|
31,483 | 11,609 | ||||||
Current portion of non-recourse notes payable
|
- | 93,370 | ||||||
Total current liabilities
|
32,296 | 133,007 | ||||||
Convertible notes payable
|
307,337 | 316,615 | ||||||
Other long-term liabilities
|
25,747 | 24,122 | ||||||
Total liabilities
|
365,380 | 473,744 | ||||||
Commitments and contingencies (Note 8)
|
||||||||
Stockholders' deficit:
|
||||||||
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding
|
- | - | ||||||
Common stock, par value $0.01 per share, 250,000 shares authorized; 139,724 and 139,680 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively
|
1,397 | 1,397 | ||||||
Additional paid-in capital
|
(234,368 | ) | (161,750 | ) | ||||
Accumulated other comprehensive loss
|
(2,739 | ) | (1,885 | ) | ||||
Retained earnings (accumulated deficit)
|
120,226 | (42,035 | ) | |||||
Total stockholders' deficit
|
(115,484 | ) | (204,273 | ) | ||||
Total liabilities and stockholders' deficit
|
$ | 249,896 | $ | 269,471 |
Nine Months Ended
September 30, |
||||||||
2012
|
2011
|
|||||||
Cash flows from operating activities
|
||||||||
Net income
|
$ | 162,261 | $ | 160,447 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Discounts and deferred issuance costs
|
10,507 | 7,342 | ||||||
Other amortization, depreciation and accretion
|
804 | 1,032 | ||||||
Loss on retirement or conversion of convertible notes
|
- | 766 | ||||||
Hedge adjustment - ineffectiveness and reclassifications from OCI for transactions probable of not occuring
|
(372 | ) | - | |||||
Stock-based compensation expense
|
675 | 256 | ||||||
Tax expense from stock-based compensation arrangements
|
(42 | ) | (120 | ) | ||||
Deferred taxes
|
6,523 | 25,117 | ||||||
Changes in assets and liabilities:
|
||||||||
Receivables from licensees
|
600 | 469 | ||||||
Prepaid and other current assets
|
5,266 | 1,881 | ||||||
Other assets
|
(1,163 | ) | (6,642 | ) | ||||
Accounts payable
|
285 | (2,655 | ) | |||||
Accrued legal settlement
|
(27,500 | ) | (37,500 | ) | ||||
Accrued liabilities
|
2,028 | 1,342 | ||||||
Other long-term liabilities
|
(1,250 | ) | (27,099 | ) | ||||
Net cash provided by operating activities
|
158,622 | 124,636 | ||||||
Cash flows from investing activities
|
||||||||
Purchases of investments
|
(25,992 | ) | (71,697 | ) | ||||
Maturities of investments
|
36,799 | 39,146 | ||||||
Issuance of notes receivable
|
(48,264 | ) | - | |||||
Acquisition of property and equipment
|
(18 | ) | - | |||||
Net cash used in investing activities
|
(37,475 | ) | (32,551 | ) | ||||
Cash flows from financing activities
|
||||||||
Repurchase of convertible notes
|
- | (134,464 | ) | |||||
Repayment of non-recourse notes
|
(93,370 | ) | (89,002 | ) | ||||
Payment of debt issuance costs
|
(845 | ) | - | |||||
Net proceeds from the issuance of convertible notes
|
- | 149,712 | ||||||
Purchase of call options
|
- | (20,765 | ) | |||||
Proceeds from issue of warrants
|
- | 10,868 | ||||||
Cash dividends paid
|
(62,886 | ) | (62,876 | ) | ||||
Net cash used in financing activities
|
(157,101 | ) | (146,527 | ) | ||||
Net decrease in cash and cash equivalents
|
(35,954 | ) | (54,442 | ) | ||||
Cash and cash equivalents at beginning of the year
|
168,544 | 211,574 | ||||||
Cash and cash equivalents at end of period
|
$ | 132,590 | $ | 157,132 | ||||
Supplemental cash flow information
|
||||||||
Cash paid for income taxes
|
$ | 76,000 | $ | 66,000 | ||||
Cash paid for interest
|
$ | 12,843 | $ | 20,004 |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||||
Licensee
|
Product Name
|
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Genentech, Inc. (Genentech)
|
Avastin®
|
30 | % | 28 | % | 31 | % | 30 | % | |||||||||
Herceptin®
|
36 | % | 38 | % | 35 | % | 34 | % | ||||||||||
Lucentis®
|
15 | % | 15 | % | 18 | % | 16 | % | ||||||||||
Elan Corporation, Plc (Elan)
|
Tysabri®
|
14 | % | 14 | % | 12 | % | 11 | % |
Three Months Ended
September 30, |
Nine Months Ended
September 30, |
|||||||||||||||
Net Income per Basic and Diluted Share:
|
2012
|
2011
|
2012
|
2011
|
||||||||||||
(In thousands except per share amounts)
|
||||||||||||||||
Numerator
|
||||||||||||||||
Net income used to compute net income per basic share
|
$ | 48,575 | $ | 45,916 | $ | 162,261 | $ | 160,447 | ||||||||
Add back interest expense for convertible notes, net of estimated tax of approximately $4,000 and $0.5 million for the three months ended September 30, 2012 and 2011, respectively and approximately $21,000 and $1.8 million for the nine months ended September 30, 2012 and 2011, respectively (see Note 9)
|
6 | 841 | 40 | 3,391 | ||||||||||||
Income used to compute net income per diluted share
|
$ | 48,581 | $ | 46,757 | $ | 162,301 | $ | 163,838 | ||||||||
Denominator
|
||||||||||||||||
Total weighted-average shares used to compute net income per basic share
|
139,715 | 139,680 | 139,693 | 139,665 | ||||||||||||
Restricted stock outstanding
|
110 | 12 | 93 | 21 | ||||||||||||
Effect of dilutive stock options
|
18 | 13 | 16 | 13 | ||||||||||||
Assumed conversion of Series 2012 Notes
|
7,008 | - | 7,427 | - | ||||||||||||
Assumed conversion of May 2015 Notes
|
2,609 | - | 2,825 | - | ||||||||||||
Assumed conversion of February 2015 Notes
|
166 | 27,314 | 624 | 27,314 | ||||||||||||
Assumed conversion of 2012 Notes
|
- | - | - | 19,743 | ||||||||||||
Weighted-average shares used to compute net income per diluted share
|
149,626 | 167,019 | 150,678 | 186,756 | ||||||||||||
Net income per basic share
|
$ | 0.35 | $ | 0.33 | $ | 1.16 | $ | 1.15 | ||||||||
Net income per diluted share
|
$ | 0.32 | $ | 0.28 | $ | 1.08 | $ | 0.88 |
September 30, 2012
|
December 31, 2011
|
|||||||||||||||||||||||
Level 1
|
Level 2
|
Total
|
Level 1
|
Level 2
|
Total
|
|||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||
Financial assets:
|
||||||||||||||||||||||||
Money market funds
|
$ | 128,962 | $ | - | $ | 128,962 | $ | 163,368 | $ | - | $ | 163,368 | ||||||||||||
Certificate of deposit
|
- | 20,000 | 20,000 | - | - | - | ||||||||||||||||||
Corporate debt securities
|
- | 23,772 | 23,772 | - | 44,877 | 44,877 | ||||||||||||||||||
Commercial paper
|
- | - | - | - | 8,996 | 8,996 | ||||||||||||||||||
U.S. government sponsored agency bonds
|
2,004 | - | 2,004 | 2,015 | - | 2,015 | ||||||||||||||||||
U.S. treasury securities
|
2,001 | - | 2,001 | 5,513 | - | 5,513 | ||||||||||||||||||
Foreign currency hedge contracts
|
- | 562 | 562 | - | 6,838 | 6,838 | ||||||||||||||||||
Total
|
$ | 132,967 | $ | 44,334 | $ | 177,301 | $ | 170,896 | $ | 60,711 | $ | 231,607 | ||||||||||||
Financial liabilities:
|
||||||||||||||||||||||||
Foreign currency hedge contracts
|
$ | - | $ | 4,446 | $ | 4,446 | $ | - | $ | 9,783 | $ | 9,783 |
September 30, 2012
|
December 31, 2011
|
|||||||||||||||||||||||
Carrying Value
|
Fair Value
Level 2
|
Fair Value
Level 3
|
Carrying Value
|
Fair Value
Level 2
|
Fair Value
Level 3
|
|||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||
Assets:
|
||||||||||||||||||||||||
Merus Labs Note Receivable
|
$ | 35,000 | $ | 34,999 | $ | - | $ | - | $ | - | $ | - | ||||||||||||
Senior Secured Note Receivable
|
9,922 | 9,813 | - | - | - | - | ||||||||||||||||||
Other Note Receivable
|
1,750 | - | 1,750 | - | - | - | ||||||||||||||||||
Total
|
$ | 46,672 | $ | 44,812 | $ | 1,750 | $ | - | $ | - | $ | - | ||||||||||||
Liabilities:
|
||||||||||||||||||||||||
Series 2012 Notes
|
$ | 164,065 | $ | 239,413 | $ | - | $ | - | $ | - | $ | - | ||||||||||||
May 2015 Notes
|
142,282 | 191,152 | - | 138,952 | 156,123 | - | ||||||||||||||||||
February 2015 Notes
|
990 | 1,338 | - | 177,663 | 191,475 | - | ||||||||||||||||||
Non-recourse Notes
|
- | - | - | 93,370 | 95,237 | - | ||||||||||||||||||
Total
|
$ | 307,337 | $ | 431,903 | $ | - | $ | 409,985 | $ | 442,835 | $ | - |
Summary of Available-For-Sale Securities
|
Amortized Cost
|
Gross Unrealized Gains
|
Gross Unrealized Losses
|
Estimated Fair Value
|
||||||||||||
(In thousands)
|
||||||||||||||||
September 30, 2012:
|
||||||||||||||||
Money market funds
|
$ | 128,962 | $ | - | $ | - | $ | 128,962 | ||||||||
Certificate of deposit
|
20,000 | - | - | 20,000 | ||||||||||||
Corporate debt securities
|
23,735 | 37 | - | 23,772 | ||||||||||||
U.S. government sponsored agency bonds
|
2,001 | 3 | - | 2,004 | ||||||||||||
U.S. treasury securities
|
1,999 | 2 | - | 2,001 | ||||||||||||
Total
|
$ | 176,697 | $ | 42 | $ | - | $ | 176,739 | ||||||||
December 31, 2011:
|
||||||||||||||||
Money market funds
|
$ | 163,368 | $ | - | $ | - | $ | 163,368 | ||||||||
Corporate debt securities
|
44,863 | 57 | (43 | ) | 44,877 | |||||||||||
Commercial paper
|
8,997 | - | (1 | ) | 8,996 | |||||||||||
U.S. government sponsored agency bonds
|
2,003 | 12 | - | 2,015 | ||||||||||||
U.S. treasury securities
|
5,494 | 19 | - | 5,513 | ||||||||||||
Total
|
$ | 224,725 | $ | 88 | $ | (44 | ) | $ | 224,769 |
Classification on Condensed Consolidated Balance Sheets:
|
September 30,
2012 |
December 31,
2011 |
||||||
(In thousands)
|
||||||||
Cash equivalents
|
$ | 128,962 | $ | 165,367 | ||||
Restricted investment
|
20,000 | - | ||||||
Short-term investments
|
27,777 | 42,301 | ||||||
Long-term investments
|
- | 17,101 | ||||||
Total
|
$ | 176,739 | $ | 224,769 |
Available-For-Sale Securities by Contractual Maturity
|
September 30, 2012
|
December 31, 2011
|
||||||||||||||
(In thousands)
|
Amortized Cost
|
Fair Value
|
Amortized Cost
|
Fair Value
|
||||||||||||
Less than one year
|
$ | 176,697 | $ | 176,739 | $ | 207,630 | $ | 207,668 | ||||||||
Greater than one year but less than five years
|
- | - | 17,095 | 17,101 | ||||||||||||
Total
|
$ | 176,697 | $ | 176,739 | $ | 224,725 | $ | 224,769 |
Euro Forward Contracts
|
September 30, 2012
|
December 31, 2011
|
|||||||||||||||||||
(In thousands)
|
(In thousands)
|
||||||||||||||||||||
Currency
|
Settlement Price
($ per Euro)
|
Type
|
Notional Amount
|
Fair Value
|
Notional Amount
|
Fair Value
|
|||||||||||||||
Euro
|
1.400 |
Sell Euro
|
$ | - | $ | - | $ | 25,150 | $ | 1,837 | |||||||||||
Euro
|
1.200 |
Sell Euro
|
- | - | 117,941 | (9,783 | ) | ||||||||||||||
Euro
|
1.230 |
Sell Euro
|
55,246 | (2,636 | ) | - | - | ||||||||||||||
Euro
|
1.240 |
Sell Euro
|
10,850 | (462 | ) | - | - | ||||||||||||||
Euro
|
1.270 |
Sell Euro
|
44,450 | (890 | ) | - | - | ||||||||||||||
Euro
|
1.281 |
Sell Euro
|
36,814 | (458 | ) | - | - | ||||||||||||||
Euro
|
1.300 |
Sell Euro
|
91,000 | 562 | - | - | |||||||||||||||
Total
|
$ | 238,360 | $ | (3,884 | ) | $ | 143,091 | $ | (7,946 | ) |
Euro Option Contracts
|
September 30, 2012
|
December 31, 2011
|
|||||||||||||||||||
(In thousands)
|
(In thousands)
|
||||||||||||||||||||
Currency
|
Strike Price
($ per Euro)
|
Type
|
Notional Amount
|
Fair Value
|
Notional Amount
|
Fair Value
|
|||||||||||||||
Euro
|
1.510 |
Purchased call option
|
$ | - | $ | - | $ | 27,126 | $ | - | |||||||||||
Euro
|
1.315 |
Purchased call option
|
- | - | 129,244 | 5,001 | |||||||||||||||
Total
|
$ | - | $ | - | $ | 156,370 | $ | 5,001 |
Cash Flow Hedge
|
Location
|
September 30, 2012
|
December 31, 2011
|
|||||||
(In thousands)
|
||||||||||
Euro contracts
|
Prepaid and other current assets
|
$ | 476 | $ | 1,837 | |||||
Euro contracts
|
Other assets
|
$ | 86 | $ | - | |||||
Euro contracts
|
Accrued liabilities
|
$ | 2,636 | $ | 4,134 | |||||
Euro contracts
|
Other long-term liabilities
|
$ | 1,810 | $ | 648 |
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
(In thousands)
|
||||||||||||||||
Net gain (loss) recognized in OCI, net of tax (1)
|
$ | (3,454 | ) | $ | 3,841 | $ | (1,851 | ) | $ | (4,835 | ) | |||||
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2)
|
$ | (328 | ) | $ | (440 | ) | $ | (998 | ) | $ | 146 | |||||
Net loss recognized in interest and other income, net -- cash flow hedges (3)
|
$ | (27 | ) | $ | - | $ | (54 | ) | $ | (19 | ) | |||||
Net gain recognized in interest and other income, net -- non-designated contracts (4)
|
$ | 391 | $ | - | $ | 391 | $ | - | ||||||||
Amount excluded from effectiveness testing
|
$ | - | $ | - | $ | - | $ | - |
September 30,
2012
|
December 31,
2011
|
|||||||
(In thousands)
|
||||||||
Compensation
|
$ | 1,872 | $ | 1,341 | ||||
Interest payable
|
3,087 | 3,351 | ||||||
Deferred revenue
|
- | 1,713 | ||||||
Foreign currency hedge
|
2,636 | 4,134 | ||||||
Dividend payable
|
21,109 | 52 | ||||||
Other
|
2,779 | 1,018 | ||||||
Total
|
$ | 31,483 | $ | 11,609 |
Principal Balance Outstanding
|
Carrying Value
|
|||||||||||||
Description
|
Maturity Date
|
September 30,
2012
|
September 30,
2012
|
December 31,
2011
|
||||||||||
(In thousands)
|
||||||||||||||
Convertible Notes
|
||||||||||||||
Series 2012 Notes
|
February 15, 2015
|
$ | 179,000 | $ | 164,065 | $ | - | |||||||
May 2015 Notes
|
May 1, 2015
|
$ | 155,250 | 142,282 | 138,952 | |||||||||
February 2015 Notes
|
February 15, 2015
|
$ | 1,000 | 990 | 177,663 | |||||||||
Non-recourse Notes
|
September 15, 2012
|
$ | - | - | 93,370 | |||||||||
Total
|
$ | 307,337 | $ | 409,985 |
·
|
During any fiscal quarter commencing after the fiscal quarter ending December 31, 2011, if the closing price of the Company’s common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the Series 2012 Notes on the last day of such preceding fiscal quarter;
|
·
|
During the five business-day period immediately after any five consecutive trading-day period in which the trading price per $1,000 principal amount of the Series 2012 Notes for each trading day of that measurement period was less than 98% of the product of the closing price of the Company’s common stock and the conversion rate for the Series 2012 Notes for that trading day;
|
·
|
Upon the occurrence of certain corporate transactions as provided in the Indenture; or
|
·
|
Anytime, at the holder’s option, beginning on August 15, 2014.
|
September 30,
2012
|
December 31,
2011
|
|||||||
(In thousands)
|
||||||||
Principal amount of the Series 2012 Notes
|
$ | 179,000 | $ | - | ||||
Unamortized discount of liability component
|
(14,935 | ) | - | |||||
Net carrying value of the Series 2012 Notes
|
$ | 164,065 | $ | - |
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
(In thousands)
|
||||||||||||||||
Contractual coupon interest
|
$ | 1,287 | $ | - | $ | 3,836 | $ | - | ||||||||
Amortization of debt issuance costs
|
279 | - | 826 | - | ||||||||||||
Amortization of debt discount
|
1,439 | - | 4,219 | - | ||||||||||||
Total
|
$ | 3,005 | $ | - | $ | 8,881 | $ | - |
September 30,
2012
|
December 31,
2011
|
|||||||
(In thousands)
|
||||||||
Principal amount of the May 2015 Notes
|
$ | 155,250 | $ | 155,250 | ||||
Unamortized discount of liability component
|
(12,968 | ) | (16,298 | ) | ||||
Net carrying value of the May 2015 Notes
|
$ | 142,282 | $ | 138,952 |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
(In thousands)
|
||||||||||||||||
Contractual coupon interest
|
$ | 1,455 | $ | 1,455 | $ | 4,366 | $ | 2,183 | ||||||||
Amortization of debt issuance costs
|
299 | 290 | 891 | 434 | ||||||||||||
Amortization of debt discount
|
1,130 | 1,051 | 3,330 | 1,570 | ||||||||||||
Total
|
$ | 2,884 | $ | 2,796 | $ | 8,587 | $ | 4,187 |
September 30,
2012
|
December 31,
2011
|
|||||||
(In thousands)
|
||||||||
Accrued lease liability
|
$ | 10,700 | $ | 10,700 | ||||
Uncertain tax position
|
12,858 | 12,774 | ||||||
Compensation
|
379 | - | ||||||
Foreign currency hedge
|
1,810 | 648 | ||||||
Total
|
$ | 25,747 | $ | 24,122 |
Stock Options
|
Restricted Stock Awards
|
|||||||||||||||||||
(In thousands except per share amounts)
|
Shares Available for Grant
|
Number of Shares
|
Weighted Average Exercise Price
|
Number of Shares
|
Weighted Average Grant-date Fair Value Per Share
|
|||||||||||||||
Balance December 31, 2011
|
4,710 | 231 | $ | 16.62 | 137 | $ | 6.09 | |||||||||||||
Granted
|
(117 | ) | - | 117 | $ | 6.30 | ||||||||||||||
Shares released
|
- | - | (44 | ) | $ | 6.73 | ||||||||||||||
Forfeited or cancelled
|
2 | (35 | ) | $ | 18.83 | (2 | ) | $ | 6.22 | |||||||||||
Balance at September 30, 2012
|
4,595 | 196 | $ | 16.22 | 208 | $ | 6.26 |
Convertible Notes
|
Conversion Rate per $1,000 Principal Amount
|
Approximate Conversion Price Per Common Share
|
Effective Date
|
||||||
Series 2012 Notes
|
166.26 | $ | 6.01 |
September 5, 2012
|
|||||
May 2015 Notes
|
145.49 | $ | 6.87 |
September 5, 2012
|
|||||
February 2015 Notes
|
166.26 | $ | 6.01 |
September 10, 2012
|
Unrealized gains (losses) on available-for-sale securities
|
Unrealized losses on cash flow hedges
|
Total Accumulated Other Comprehensive Loss
|
||||||||||
(In thousands)
|
||||||||||||
Beginning Balance at December 31, 2011
|
$ | 29 | $ | (1,914 | ) | $ | (1,885 | ) | ||||
Activity for the nine months ended September 30, 2012
|
(1 | ) | (853 | ) | (854 | ) | ||||||
Ending Balance at September 30, 2012
|
$ | 28 | $ | (2,767 | ) | $ | (2,739 | ) |
Convertible Notes
|
Conversion Rate per $1,000 Principal Amount
|
Approximate Conversion Price Per Common Share
|
Effective Date
|
||||||
May 2015 Notes
|
145.49 | $ | 6.87 |
September 5, 2012
|
|||||
Series 2012 Notes
|
166.26 | $ | 6.01 |
September 5, 2012
|
|||||
February 2015 Notes
|
166.26 | $ | 6.01 |
September 10, 2012
|
|||||
·
|
for the May 2015 Notes, the numerator equals the average closing price of PDL's common stock for the ten consecutive trading days immediately preceding the ex-dividend date, and the denominator of which is such ten day average closing price less the per share dividend amount; and
|
·
|
for the Series 2012 Notes and February 2015 Notes, the numerator equals the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date, and the denominator of which is such five day average closing price less the per share dividend amount.
|
Application Number
|
Filing Date
|
Patent Number
|
Issue Date
|
Expiration Date
|
|||||
08/477,728
|
06/07/95
|
5585089 |
12/17/96
|
06/25/13
|
|||||
08/474,040
|
06/07/95
|
5693761 |
12/02/97
|
12/02/14
|
|||||
08/487,200
|
06/07/95
|
5693762 |
12/02/97
|
06/25/13
|
|||||
08/484,537
|
06/07/95
|
6180370 |
01/30/01
|
06/25/13
|
Licensee
|
Product Names
|
|
Genentech, Inc. (Genentech)
|
Avastin
|
|
Herceptin
|
||
Xolair
|
||
Lucentis
|
||
Perjeta
|
||
Elan Corporation, Plc (Elan)
|
Tysabri
|
|
Chugai Pharmaceutical Co., Ltd. (Chugai)
|
Actemra®
|
|
Genentech Products Made or Sold in the U.S.
|
Royalty Rate
|
|||
Net sales up to $1.5 billion
|
3.0 | % | ||
Net sales between $1.5 billion and $2.5 billion
|
2.5 | % | ||
Net sales between $2.5 billion and $4.0 billion
|
2.0 | % | ||
Net sales exceeding $4.0 billion
|
1.0 | % | ||
Genentech Products Made and Sold ex-U.S.
|
||||
Net sales
|
3.0 | % |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Avastin
|
||||||||||||||||
Ex-U.S.-based Sales
|
56 | % | 56 | % | 56 | % | 56 | % | ||||||||
Ex-U.S.-based Manufacturing and Sales
|
29 | % | 19 | % | 25 | % | 19 | % | ||||||||
Herceptin
|
||||||||||||||||
Ex-U.S.-based Sales
|
70 | % | 73 | % | 70 | % | 72 | % | ||||||||
Ex-U.S.-based Manufacturing and Sales
|
37 | % | 43 | % | 38 | % | 38 | % | ||||||||
Lucentis
|
||||||||||||||||
Ex-U.S.-based Sales
|
65 | % | 60 | % | 62 | % | 58 | % | ||||||||
Ex-U.S.-based Manufacturing and Sales
|
0 | % | 0 | % | 0 | % | 0 | % | ||||||||
Xolair
|
||||||||||||||||
Ex-U.S.-based Sales
|
39 | % | 41 | % | 39 | % | 40 | % | ||||||||
Ex-U.S.-based Manufacturing and Sales
|
39 | % | 41 | % | 39 | % | 40 | % |
Three Months Ended
September 30,
|
Change from Prior
|
Nine Months Ended
September 30,
|
Change from Prior
|
|||||||||||||||||||||
2012
|
2011
|
Year % |
2012
|
2011
|
Year % | |||||||||||||||||||
(Dollars in thousands)
|
||||||||||||||||||||||||
Revenues
|
||||||||||||||||||||||||
Royalties
|
$ | 85,231 | $ | 83,370 | 2 | % | $ | 288,479 | $ | 278,833 | 3 | % | ||||||||||||
License and other
|
- | 400 | -100 | % | - | 10,400 | -100 | % | ||||||||||||||||
Total revenues
|
$ | 85,231 | $ | 83,770 | 2 | % | $ | 288,479 | $ | 289,233 | 0 | % |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||||
Licensee
|
Product Name
|
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Genentech
|
Avastin
|
30 | % | 28 | % | 31 | % | 30 | % | |||||||||
Herceptin
|
36 | % | 38 | % | 35 | % | 34 | % | ||||||||||
Lucentis
|
15 | % | 15 | % | 18 | % | 16 | % | ||||||||||
Elan
|
Tysabri
|
14 | % | 14 | % | 12 | % | 11 | % |
Three Months Ended
September 30,
|
Change from Prior
|
Nine Months Ended
September 30,
|
Change from Prior
|
|||||||||||||||||||||
2012
|
2011
|
Year % |
2012
|
2011
|
Year % | |||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||
Operating expenses
|
||||||||||||||||||||||||
General and administrative
|
$ | 5,647 | $ | 3,960 | 43 | % | $ | 17,737 | $ | 13,516 | 31 | % |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Net income per basic share
|
$ | 0.35 | $ | 0.33 | $ | 1.16 | $ | 1.15 | ||||||||
Net income per diluted share
|
$ | 0.32 | $ | 0.28 | $ | 1.08 | $ | 0.88 |
·
|
During any fiscal quarter commencing after the fiscal quarter ending December 31, 2011, if the closing price of the Company’s common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the Series 2012 Notes on the last day of such preceding fiscal quarter;
|
·
|
During the five business-day period immediately after any five consecutive trading-day period in which the trading price per $1,000 principal amount of the Series 2012 Notes for each trading day of that measurement period was less than 98% of the product of the closing price of the Company’s common stock and the conversion rate for the Series 2012 Notes for that trading day;
|
·
|
Upon the occurrence of certain corporate transactions as provided in the Indenture; or
|
·
|
Anytime, at the holder’s option, beginning on August 15, 2014.
|
·
|
During any fiscal quarter ending after the quarter ending June 30, 2011, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;
|
·
|
During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
|
·
|
Upon the occurrence of specified corporate events as described further in the indenture; or
|
·
|
At any time on or after November 1, 2014.
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
(In thousands)
|
||||||||||||||||
Net gain (loss) recognized in OCI, net of tax (1)
|
$ | (3,454 | ) | $ | 3,841 | $ | (1,851 | ) | $ | (4,835 | ) | |||||
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2)
|
$ | (328 | ) | $ | (440 | ) | $ | (998 | ) | $ | 146 | |||||
Net loss recognized in interest and other income, net -- cash flow hedges (3)
|
$ | (27 | ) | $ | - | $ | (54 | ) | $ | (19 | ) | |||||
Net gain recognized in interest and other income, net -- non-designated contracts (4)
|
$ | 391 | $ | - | $ | 391 | $ | - | ||||||||
Amount excluded from effectiveness testing
|
$ | - | $ | - | $ | - | $ | - |
12.1*
|
Ratio of Earnings to Fixed Charges
|
31.1*
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
|
31.2*
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
|
32.1**
|
Certification by the Principal Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)
|
32.2**
|
Certification by the Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)
|
101.INS
|
XBRL Instance Document
|
101.SCH
|
XBRL Taxonomy Extension Schema
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase
|
*
|
Filed herewith.
|
**
|
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
|
Dated: November 5, 2012
PDL BIOPHARMA, INC. (REGISTRANT)
|
|
/s/ John P. McLaughlin
|
|
John P. McLaughlin
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
/s/ Bruce Tomlinson
|
|
Bruce Tomlinson
|
|
Vice President and Chief Financial Officer
|
|
(Principal Financial Officer)
|
|
/s/ Caroline Krumel
|
|
Caroline Krumel
|
|
Vice President of Finance
(Principal Accounting Officer)
|
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(dollars in thousands except ratios)
|
||||||||||||||||||||||||
For the Nine
|
||||||||||||||||||||||||
For the Years Ended December 31, |
Months Ended
|
|||||||||||||||||||||||
2007
|
2008
|
2009
|
2010
|
2011
|
September 30,
2012
|
|||||||||||||||||||
Earnings:
|
||||||||||||||||||||||||
Income before income taxes
|
$ | 191,073 | $ | 243,334 | $ | 280,285 | $ | 150,370 | $ | 307,428 | $ | 250,040 | ||||||||||||
Add: fixed charges
|
16,267 | 14,285 | 19,430 | 43,578 | 36,153 | 23,131 | ||||||||||||||||||
Earnings
|
$ | 207,340 | $ | 257,619 | $ | 299,715 | $ | 193,948 | $ | 343,581 | $ | 273,171 | ||||||||||||
Fixed Charges:
|
||||||||||||||||||||||||
Interest expense
|
$ | 16,200 | $ | 14,219 | $ | 19,357 | $ | 43,529 | $ | 36,102 | $ | 23,087 | ||||||||||||
Estimated interest portion of rent expense
|
67 | 66 | 73 | 49 | 51 | 44 | ||||||||||||||||||
Fixed charges
|
$ | 16,267 | $ | 14,285 | $ | 19,430 | $ | 43,578 | $ | 36,153 | $ | 23,131 | ||||||||||||
Ratio of earnings to fixed charges
|
12.75 | 18.03 | 15.43 | 4.45 | 9.50 | 11.81 |
Date: November 5, 2012
|
|
/s/ John P. McLaughlin | |
John P. McLaughlin
President and Chief Executive Officer
(Principal Executive Officer)
|
Date: November 5, 2012
|
|
/s/ Bruce Tomlinson | |
Bruce Tomlinson
Vice President and Chief Financial Officer
(Principal Financial Officer)
|
/s/ John P. McLaughlin | |
John P. McLaughlin
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
/s/ Bruce Tomlinson | |
Bruce Tomlinson
|
|
Vice President and Chief Financial Officer
|
|
(Principal Financial Officer)
|
,%FDEA%%S?.ZG,_2WH)3T5SXK_X(%_M":3\" M/^"4WQ1\5>,KRY/A?P=XGO9I50&21(3963&*-00>*=9UNS@U,)"CA[I+B9%G9XRK,621\,C+N M)!%?:'[(7_!':P^!/["GQ&^!WBSQ9_PE&F?$'4)KV6^LK(V4EGO@MXTVJSOE MD>W5P2<'@$<<^3?"K_@B+\8?!W@&7X6ZE^TEJA^"3M+YFAZ7IGV>ZO(9'9Y( M"[,?)CD9FWJK,IW-\IW&NMXW!RQ%6LIV;DFOBM;NDK:^I7,KW/-_^"16OWFK M?\$&_P!I&RN+B26VTFW\3P6B,[M]7-8W_!OO_P3E^&7[37P M!\0_$/XA:&?%&I:9XB.C:1%<7<\<6F1P10W!>,1NOS-)<$Y.0-O&-S9^O?V+ M_P#@E#J/[*'["WQ8^#=QXYL]=D^),6H1PZE'I;6Z:>;O3ULRQC,K&3;L#\,N M1QQUKT+_`()6_L$W?_!.;]G34_`UWXFM_%DE_K\^M"\ALC:*@D@MXO+V%WR1 MY& &],\/>#_%9TB;4]+TN$6=K*K22B9%2/"QK(D.T[`/O$C!)-?H&/^"6]\__ M``5K7]IG_A,K46:1[/[`_LUO,/\`Q*3I_P#Q\>9CJ?,^YTX]Z7X[_P#!+:^^ M,?\`P4S\$_M`Q^,K73[3PC':1OHK: #_V6/\`@K=^S5+\.O#ND>#8]1OM(FN+?2+9 M+2"21-5$>\QH`NYD(5CCY@!NS7T;_P`%3?VL/ALG[7/@/X<1?`I?V@/B_86L MITK2;R94T[3DNMCMO1U>.20I;JYWQX2,;MZ@FO4/V\/^"7%]^V1^UW\*OB?; M^,[70(?AO+:R2:=)IK7+WWDWHN2!()%"9`V_=;'7VKGOV\O^"16N_'K]JG1_ MC=\*?B5+\-OB1IT"033R6IN(;C9&T2R`@Y1O*9HV4JRNN`0,'.-'&X:I[#VT M]8QDF]5J]DVM;6[";7<^`/COIWBSX7?\%4OV<]7U;X)>%?V?]9U+7M+0Z=X= MU2UN8-2@;4(XGE=+;"1,4=XFX!<= /?CM\//BAXT^.]_XL\>>% M]8MM3U2ZO])S;W$=M<1306MJBR`0(I27)P06EW;5Y#?I;&`%QC!KDS;%4:JH MJG*[BFG:_?SU_$4VFE8=1117D&84444`%%%%`!1110`4444`%%%%`!1110`4 >444`%%%%`!1110`4444`%%%%`!1110`4444`?__9 ` end
Note 3 - Fair Value Measurements (Detail) - Assets and Liabilities Not Recorded at Fair Value (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
---|---|---|
Assets: | ||
Notes receivable carrying value | $ 46,672 | |
Liabilities: | ||
Notes payable carrying value | 307,337 | 409,985 |
Merus Labs Note Receivable [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
Assets: | ||
Notes receivable fair value | 34,999 | |
Merus Labs Note Receivable [Member]
|
||
Assets: | ||
Notes receivable carrying value | 35,000 | |
Senior Secured Note Receivable [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
Assets: | ||
Notes receivable fair value | 9,813 | |
Senior Secured Note Receivable [Member]
|
||
Assets: | ||
Notes receivable carrying value | 9,922 | |
Other Notes Receivable [Member] | Fair Value, Inputs, Level 3 [Member]
|
||
Assets: | ||
Notes receivable fair value | 1,750 | |
Other Notes Receivable [Member]
|
||
Assets: | ||
Notes receivable carrying value | 1,750 | |
Fair Value, Inputs, Level 2 [Member] | Series 2012 Notes [Member]
|
||
Liabilities: | ||
Notes payable fair value | 239,413 | |
Fair Value, Inputs, Level 2 [Member] | Convertible May 2015 Notes [Member]
|
||
Liabilities: | ||
Notes payable fair value | 191,152 | 156,123 |
Fair Value, Inputs, Level 2 [Member] | Convertible February 2015 Notes [Member]
|
||
Liabilities: | ||
Notes payable fair value | 1,338 | 191,475 |
Fair Value, Inputs, Level 2 [Member] | Non-Recourse Notes [Member]
|
||
Liabilities: | ||
Notes payable fair value | 95,237 | |
Fair Value, Inputs, Level 2 [Member]
|
||
Assets: | ||
Notes receivable fair value | 44,812 | |
Liabilities: | ||
Notes payable fair value | 431,903 | 442,835 |
Fair Value, Inputs, Level 3 [Member]
|
||
Assets: | ||
Notes receivable fair value | 1,750 | |
Series 2012 Notes [Member]
|
||
Liabilities: | ||
Notes payable carrying value | 164,065 | |
Convertible May 2015 Notes [Member]
|
||
Liabilities: | ||
Notes payable carrying value | 142,282 | 138,952 |
Convertible February 2015 Notes [Member]
|
||
Liabilities: | ||
Notes payable carrying value | 990 | 177,663 |
Non-Recourse Notes [Member]
|
||
Liabilities: | ||
Notes payable carrying value | $ 93,370 |
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Interest Expense For Our Series 2012 Notes (Series 2012 Notes [Member], USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended |
---|---|---|
Sep. 30, 2012
|
Sep. 30, 2012
|
|
Series 2012 Notes [Member]
|
||
Contractual coupon interest | $ 1,287 | $ 3,836 |
Amortization of debt issuance costs | 279 | 826 |
Amortization of debt discount | 1,439 | 4,219 |
Total | $ 3,005 | $ 8,881 |
Note 6 - Notes and Other Long-term Receivables (Detail) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | 3 Months Ended | |||||
---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2012
Initial Loan [Member]
Merus Labs International Inc. [Member]
|
Sep. 30, 2012
Additional Loan [Member]
Merus Labs International Inc. [Member]
|
Aug. 31, 2012
Senior Secured Note Receivable [Member]
|
Mar. 31, 2012
Senior Secured Note Receivable [Member]
|
Sep. 30, 2012
Merus Labs International Inc. [Member]
|
Sep. 30, 2012
Merus Labs International Inc. [Member]
|
|
Increase (Decrease) in Finance Receivables | $ 35.0 | ||||||
Letter of Credit Extended | 20.0 | ||||||
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred | 20.0 | ||||||
Interest Rate on Note Receivable | 13.50% | 14.00% | 12.00% | 10.00% | |||
Financing Receivable Future Principal Payments in Current Fiscal Year | 5.0 | ||||||
Financing Receivable Future Principal Payments in Two Years | 7.5 | ||||||
Financing Receivable Future Principal Payments in Three Years | 10.0 | ||||||
Financing Receivable Future Principal Payments In Four Years | 12.5 | ||||||
Financing Receivable, Gross | $ 10.0 | $ 7.5 |
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - May 2015 Notes (USD $)
|
Sep. 30, 2012
|
Dec. 31, 2011
|
---|---|---|
Net carrying value of the May 2015 Notes | $ 307,337,000 | $ 409,985,000 |
Convertible May 2015 Notes [Member]
|
||
Principal amount of the May 2015 Notes | 155,250,000 | 155,250,000 |
Unamortized discount of liability component | (12,968,000) | (16,298,000) |
Net carrying value of the May 2015 Notes | $ 142,282,000 | $ 138,952,000 |
Note 5 - Foreign Currency Hedging (Detail) - Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
---|---|---|
Prepaid And Other Current Assets [Member]
|
||
Euro contracts | $ 476 | $ 1,837 |
Other Assets [Member]
|
||
Euro contracts | 86 | |
Accrued Liabilities [Member]
|
||
Euro contracts | 2,636 | 4,134 |
Other Long-Term Liabilities [Member]
|
||
Euro contracts | $ 1,810 | $ 648 |
Note 14 - Accumulated Other Comprehensive Income (Loss) (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] |
|
Note 10 - Other Long-Term Liabilities (Detail) - Other Long-term Liabilities (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
---|---|---|
Accrued lease liability | $ 10,700 | $ 10,700 |
Uncertain tax position | 12,858 | 12,774 |
Compensation | 379 | |
Foreign currency hedge | 1,810 | 648 |
Total | $ 25,747 | $ 24,122 |
Note 3 - Fair Value Measurements (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Liabilities Not Recorded At Fair Value [Table Text Block] |
|
Note 8 - Commitments and Contingencies (Detail) (USD $)
In Millions, unless otherwise specified |
9 Months Ended | |||||
---|---|---|---|---|---|---|
Sep. 30, 2012
|
Dec. 31, 2011
|
Jul. 07, 2011
|
Sep. 30, 2012
Past U.S. Based Sales [Member]
|
Sep. 30, 2012
Future U.S. Based Sales [Member]
|
Sep. 30, 2012
Europe [Member]
|
|
RoyaltyRevenueGeographicConcentration | 35.00% | |||||
Royalty Rate | 3.75% | 3.75% | ||||
Number of Genentech's Claims Dismissed by Court | 2 | |||||
Number of PDL's Claims Upheld by Court | 4 | |||||
Number of PDL's claims for relief relating to the 2003 settlement agreement | 5 | |||||
Number of PDL's claims dismissed by the court | 1 | |||||
Operating Leases, Future Minimum Payments Due (in Dollars) | $ 103.0 | |||||
Loss Contingency, Estimate of Possible Loss (in Dollars) | $ 10.7 | $ 10.7 |
Note 4 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-For-Sale Securities Balance Sheet Classification (USD $)
In Thousands, unless otherwise specified |
Sep. 30, 2012
|
Dec. 31, 2011
|
---|---|---|
Cash equivalents | $ 128,962 | $ 165,367 |
Restricted investment | 20,000 | |
Short-term investments | 27,777 | 42,301 |
Long-term investments | 17,101 | |
Total | $ 176,739 | $ 224,769 |
Note 2 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (Parentheticals) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
Estimated tax on interest expense for convertible notes (in Dollars) | $ 4 | $ 500 | $ 21 | $ 1,800 |
Note 9 - Convertible Notes and Non-recourse Notes (Detail) - Convertible and Non-recourse Notes Activity (USD $)
In Thousands, unless otherwise specified |
9 Months Ended | |
---|---|---|
Sep. 30, 2012
|
Dec. 31, 2011
|
|
Convertible Notes | ||
Carrying Value | $ 307,337 | $ 409,985 |
Series 2012 Notes [Member]
|
||
Convertible Notes | ||
Maturity Date | Feb. 15, 2015 | |
Principal Balance Outstanding | 179,000 | |
Carrying Value | 164,065 | |
Convertible May 2015 Notes [Member]
|
||
Convertible Notes | ||
Maturity Date | May 01, 2015 | |
Principal Balance Outstanding | 155,250 | 155,250 |
Carrying Value | 142,282 | 138,952 |
Convertible February 2015 Notes [Member]
|
||
Convertible Notes | ||
Maturity Date | Feb. 15, 2015 | |
Principal Balance Outstanding | 1,000 | |
Carrying Value | 990 | 177,663 |
Non-Recourse Notes [Member]
|
||
Convertible Notes | ||
Maturity Date | Sep. 15, 2012 | |
Carrying Value | $ 93,370 |
Note 13 - Income Taxes (Detail)
|
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | 35.00% | 35.00% | 35.00% | 35.00% |
Note 5 - Foreign Currency Hedging (Detail) - Derivative Instruments Designated as Cash Flow Hedges Effect on Other Comprehensive Income (Loss) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|||||||||||||
Net gain (loss) recognized in OCI, net of tax (1) | $ (3,454) | [1] | $ 3,841 | [1] | $ (1,851) | [1] | $ (4,835) | [1] | ||||||||
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax (2) | (328) | [2] | (440) | [2] | (998) | [2] | 146 | [2] | ||||||||
Amount excluded from effectiveness testing | 0 | 0 | 0 | 0 | ||||||||||||
Cash Flow Hedges [Member]
|
||||||||||||||||
Net loss recognized in interest and other income, net -- cash flow hedges (3) | (27) | [3] | [3] | (54) | [3] | (19) | [3] | |||||||||
Net gain recognized in interest and other income, net -- non-designated contracts (4) | (27) | [3] | [3] | (54) | [3] | (19) | [3] | |||||||||
Non-designated Contracts [Member]
|
||||||||||||||||
Net loss recognized in interest and other income, net -- cash flow hedges (3) | 391 | [4] | [4] | 391 | [4] | [4] | ||||||||||
Net gain recognized in interest and other income, net -- non-designated contracts (4) | $ 391 | [4] | [4] | $ 391 | [4] | [4] | ||||||||||
|
Note 3 - Fair Value Measurements
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Text Block] |
3. Fair Value
Measurements
The
fair value of our financial instruments are estimates of
the amounts that would be received if we were to sell an
asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement
date or exit price. The assets and liabilities are
categorized and disclosed in one of the following three
categories:
Level
1 – based on quoted market prices in active markets
for identical assets and liabilities;
Level
2 – based on quoted market prices for similar assets
and liabilities, using observable market based inputs or
unobservable market based inputs corroborated by market
data; and
Level
3 – based on unobservable inputs using
management’s best estimate and assumptions when
inputs are unavailable.
The
following tables present the fair value of our financial
instruments measured at fair value on a recurring basis by
level within the valuation hierarchy.
The
fair value of the certificate of deposit is priced using
quoted market prices for similar instruments, non-binding
market prices that are corroborated by observable market
data. The certificate of deposit is restricted as it was
purchased to collateralize the line of credit for Merus
Labs International, Inc., see Note 6.
Corporate
debt securities consist primarily of U.S. corporate bonds.
The fair value of corporate debt securities is estimated
using recently executed transactions or market quoted
prices, where observable. Independent pricing sources are
also used for valuation.
The
fair value of commercial paper is estimated based on
observable inputs of comparable securities.
The
fair value of foreign currency hedging contracts is
estimated based on pricing models using readily observable
inputs from actively quoted markets and is disclosed
on a gross basis.
The
following tables present the fair value of assets and
liabilities not subject to fair value recognition by level
within the valuation hierarchy:
As
of September 30, 2012, the fair values of our Merus Labs
Note Receivable, our Senior Secured Note Receivable, and
our Other Notes Receivable were determined using one or
more discounted cash flow models, incorporating expected
payments and the interest rate extended on the notes with
fixed interest rates and incorporating expected payments
for notes with a variable rate of return.
The
fair values of our convertible notes and our Non-recourse
Notes, as defined herein, were determined using quoted
market pricing or dealer quotes of our then outstanding
notes.
|
Note 14 - Accumulated Other Comprehensive Income (Loss) (Detail) - Accumulated Other Comprehensive Income (Loss), Net of Tax (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
Beginning Balance at December 31, 2011 | $ 29 | |||
Beginning Balance at December 31, 2011 | (1,914) | |||
Beginning Balance at December 31, 2011 | (1,885) | |||
Activity for the nine months ended September 30, 2012 | (14) | (55) | (1) | (8) |
Activity for the nine months ended September 30, 2012 | (3,126) | 4,281 | (853) | (4,981) |
Activity for the nine months ended September 30, 2012 | (3,140) | 4,226 | (854) | (4,989) |
Ending Balance at September 30, 2012 | 28 | 28 | ||
Ending Balance at September 30, 2012 | (2,767) | (2,767) | ||
Ending Balance at September 30, 2012 | $ (2,739) | $ (2,739) |
'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$ '!E;G-E+"!N970\+W-T '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$ '1087)T7V5A.3 '0O:F%V87-C 3X-"B`@ M("`\=&%B;&4@8VQA #PO '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$ F5D(&QO 3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E M83DW-F)C95]E-S$S7S0U93E?83!D-%]C-#(X,&0S,#ED9#@-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO96$Y-S9B8V5?93 '0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R 2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA '0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ '1087)T7V5A.3 '0O M:F%V87-C 3X-"B`@("`\ M=&%B;&4@8VQA F5D("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,"PP,#`\ '1087)T7V5A.3 '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA '0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S 2!O<&5R871I;F<@86-T:79I=&EE '0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ 6UE;G0@;V8@;F]N+7)E8V]U '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ '0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S '0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S &5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XW-BPP,#`\ '1087)T7V5A.3 '0O:F%V87-C 3X-"B`@("`\=&%B;&4@8VQA 2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S M/&)R/CPO 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4 M:&4-"B`@("`@#0H@("`@("`@(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@0V]N M9&5N 2!A8V-E<'1E9"!A8V-O M=6YT:6YG('!R:6YC:7!L97,@*$=!05`I(&9O2P@4$1, M+"!W92P@=7,@;W(@;W5R*2!B96QI979E 65A6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@ M("`@("`@(&%C8V]M<&%N>6EN9R!#;VYD96YS960@0V]N 6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@/&9O;G0@ 6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@ M F5D(&]R:6=I M;F%T:6]N(&9E97,L(&EF(&%N>2XF(S$V,#LF(S$V,#M296QA=&5D#0H@("`- M"B`@("`@("`@9F5E 6QE/3-$)U!!1$1)3D 6QE/3-$)U!!1$1)3D "<^#0H@#0H@("`@("`@("`@ M("`@("`@)B,Q-C`[#0H@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ "<^#0H@("`@(`T*("`@("`@("`@ M("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@ M("`@("`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#(R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M 6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@#0H@ M("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU, M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E 6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^3&EC96YS964\+V9O;G0^#0H@(`T*("`@ M("`@("`@("`@("`@(#PO9&EV/@T*("`@(`T*("`@("`@("`@("`@("`\+W1D M/@T*(`T*("`@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$)U!!1$1)3D 6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`@(`T*("`@("`@("`@("`@("`@("`@/&9O;G0@ 6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<^#0H@("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@ M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=( M5#H@,'!T)R!A;&EG;CTS1&-E;G1E 6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@ M#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@ M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=) M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E M 6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@#0H@("`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E 6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=( M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U! M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E M;G1E 6QE/3-$)V)A8VMG 6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@(`T*("`@("`@("`@("`@("`@ M("`@/&9O;G0@ 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`- M"B`@("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0R-24^#0H@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`-"B`@("`@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^079A 6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@("`F M(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@ M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@ M("`@/&9O;G0@ 6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR.#PO9F]N=#X- M"B`@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@ 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXE/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@ M(`T*("`@("`@("`@("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@ M/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@ M("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^ M#0H@#0H@("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M#0H@("`@("`@("`@("`@("`@/&9O;G0@ 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`- M"B`@("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0R-24^#0H@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`-"B`@("`@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^2&5R8V5P M=&EN/"]F;VYT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`W,"4[(%9%4E1)0T%,+4%,24=..B!T97AT+71O<"<^)B,Q-S0[ M/"]F;VYT/CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\+V1I=CX- M"B`@("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`-"B`@("`@("`@ M("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@ M("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@#0H@("`@("`@("`@("`@ M("`@)B,Q-C`[#0H@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@("`@ M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@ 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@("`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@(`T*("`@ M("`@("`@("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X- M"B`-"B`@("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@ M("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@ M("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@ 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS M-3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@ M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@ 6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXE/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+W1D M/@T*(`T*("`@("`@("`@("`@/"]T 6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`@(`T*("`@("`@("`@("`@("`@("`@/&9O;G0@ M 6QE/3-$)T9/ M3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY,=6-E;G1I 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/@T* M("`@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@("`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@(`T*("`@("`@("`@ M("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@ M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@ M("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@ M("`@("`@/&9O;G0@ 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ.#PO9F]N M=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@ 6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXE/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T* M("`@("`@("`@("`@/"]T 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(U)3X-"B`@(`T*("`@("`@("`@ M("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@ M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`-"B`@("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@ M(#PO=&0^#0H@#0H@("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@#0H@ M("`@("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@("`@("`@("`@("`\+W1D M/@T*(`T*("`@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$.24@ 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@#0H@("`@("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@("`@("`@ M("`@("`\+W1D/@T*(`T*("`@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^#0H@(`T*("`@("`@("`@("`@("`@("8C,38P.PT* M("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@ M("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@ M("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ 6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@("`@("`@("`@ M("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@(`T*("`@ M("`@("`@("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]T9#X- M"B`-"B`@("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`-"B`@("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@ M("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX- M"B`@#0H@("`@("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@("`@("`@("`@ M("`\+W1D/@T*(`T*("`@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$.24@ 6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@ M("`@("`@("`@("`\+W1D/@T*(`T*("`@("`@("`@("`@/"]T 6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY%;&%N#0H@#0H@("`@("`@("`@("`@("`@("!#;W)P;W)A=&EO;BP@4&QC M("A%;&%N*3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@("`@/"]D:78^ M#0H@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@ M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^ M#0H@("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`-"B`@("`@("`@("`@ M("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0R-24^#0H@#0H@("`@("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1% M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`-"B`@("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\ M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN M;&EN92<^5'ES86)R:3PO9F]N=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@-S`E.R!615)424-!3"U!3$E'3CH@=&5X="UT M;W`G/B8C,3 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@ M("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@ M#0H@("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@ M("`@("`@("`@("`@("`@/&9O;G0@ 6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXQ-#PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@ M("`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@ 6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXE/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+W1D/@T*(`T*("`@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24^#0H@(`T*("`@("`@("`@("`@("`@("8C,38P.PT*("`-"B`@ M("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`-"B`@("`@("`@("`@("`@("`F(S$V,#L-"B`@#0H@("`@("`@ M("`@("`@(#PO=&0^#0H@#0H@("`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE 6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@ 6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI M8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY&;W)E M:6=N#0H@("`-"B`@("`@("`@0W5R 6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X-"B`-"B`@("`@("`@/&9O;G0@ 2!H961G97,@=&\@;6%N86=E(&5X<&]S=7)E 6%L='D@ 2!R979E M;G5E 2!O8G-E F5D(&=A:6X@;W(@;&]S M